Background: Several studies suggest that inhaled and oral corticosteroids repress systemic inflammation in chronic obstructive pulmonary disease (COPD). However, the cytokines that may respond to these medications are unclear. Method: We used data from 41 patients with a history of stable moderate COPD (average age 64 years) who were randomised to inhaled fluticasone (500 mg twice daily from a Diskus inhaler), oral prednisone (30 mg daily) or placebo for 2 weeks. Using a multiplexed array system, different serum cytokines that have been implicated in COPD pathogenesis were measured. Results: We found that compared with placebo, inhaled fluticasone significantly reduced levels of soluble tumour necrosis factor receptor-2 (sTNF-R2) by 24% (95% CI, 738%; p ¼ 0.01), monocyte chemoattractant protein-1 by 20% (95% CI, 532%; p ¼ 0.01), interferon gamma inducible CXCL10 (IP-10) by 43% (95% CI, 366%; p ¼ 0.04), and soluble L-selectin levels by 15% (95% CI, 128%; p ¼ 0.04). Compared with placebo, oral prednisone reduced levels of sTNF-R2 by 26% (95% CI, 1536%; p < 0.001), L-selectin by 22% (95% CI, 834%; p ¼ 0.004), intercellular adhesion molecule-1 by 31% (95% CI, 948%; p ¼ 0.01), pulmonary and activationregulated chemokine (PARC) by 18% (95% CI, 232%; p ¼ 0.03) and IP-10 by 40% (95% CI, 064%; p ¼ 0.05). sTNF-R2, L-selectin and IP-10 were significantly reduced by both oral and inhaled corticosteroids. The other cytokines were not significantly repressed by either oral or inhaled corticosteroids. Conclusions: In summary, inhaled and oral corticosteroids significantly repressed a selected number of systemic cytokines in patients with stable, moderate COPD; most of the steroidresponsive cytokines appear to be chemoattractants.
Introduction
Chronic obstructive pulmonary disease (COPD) is a worldwide epidemic, affecting over 5% of the adult population [Pauwels and Rabe, 2004] . Since 1970, the age-adjusted mortality rates from COPD have increased by 103%. At the same time, mortality from other causes has decreased by 32% [Jemal et al. 2005] . Discouragingly, COPD is the only major cause of death for which the morbidity and mortality rates are still increasing. There is credible evidence that systemic inflammation, which has been implicated in all of these disorders, exists in stable COPD and its intensity increases along the COPD severity gradient [Gan et al. 2004; Sin and Man, 2003] . Inhaled corticosteroids reduce exacerbations and improve health status [Burge et al. 2000 ]. Whether inhaled corticosteroids can repress systemic inflammation is not entirely clear. In the current exploratory study, we built on the results of the study by Pinto-Plata and colleagues, which had previously identified a panel of systemic biomarkers that distinguished patients with COPD from control subjects [Pinto-Plata et al. 2007 ]. The selected biomarker panel was then used to assess the effects of inhaled and oral corticosteroids on systemic inflammation in COPD.
Methods

Study design
The current study is an extension of a clinical trial, which we had previously reported . Briefly, we recruited 41 patients aged 45 to 80 years, who had stable symptoms of COPD in the previous 3 months before study entry. All patients had an FEV 1 (forced expiratory volume in 1 minute) after bronchodilation with 400 mg salbutamol that was 2590% of predicted, a change of less than 20% of predicted FEV 1 , 30 minutes following bronchodilation, and a FEV 1 /forced vital capacity (FVC) of less than 75%. Patients also had a history of at least 10 pack-years of smoking or prolonged exposure (>10 years) to noxious gases (e.g. diesel fumes). At the first visit, patients, who were taking inhaled corticosteroids, were asked to immediately discontinue the use of these medications. They were allowed to take other medications for their COPD. None of the patients took theophyllines at the time of study entry and no new medications were commenced between the first and second visits. The patients returned 4 weeks later for a second visit, at which point, they were randomised into one of the three arms of the trial: placebo capsules and a placebo puffer, fluticasone (500 mg twice daily) and placebo capsules, or prednisone (30 mg once daily) and a placebo puffer. The trial period lasted 2 weeks. At each visit, participants' serum was collected and frozen immediately in À70 C conditions.
Biomarker measurements
A panel of biomarkers was analysed using the SearchLight Multiplex Array System TM (Pierce Endogen, Rockford, IL), which employs a multiplexed sandwich enzyme-linked immunosorbent assay technology (http://www.endogen.com). The a priori chosen biomarkers are shown in Table 1 : soluble tumour necrosis factor receptor 2 (sTNF-R2), interferon gamma inducible CXCL10 (IP-10), L-selectin, tissue inhibitor of metalloproteinase-1 (TIMP1), myeloid progenitor inhibitory factor-1 (MPIF-1), prolactin, intercellular adhesion molecule-1 (ICAM-1), vascular endothelial growth factor (VEGF), monocyte chemoattractant protein-1 (MCP-1), interleukin (IL)-12p40, brain-derived neurotrophic growth factor (BDNF), ErbB2, IL-1Ra, macrophage inflammatory protein-1b (MIP-1b), adipocyte complement-related protein of 30 kDa (ACRP30), epithelial neutrophil activating peptide (ENA78), nerve growth factor (bNGF), IL-15, transforming growth factor-a (TGF-a), eotaxin-2, interferon-g (IFN-g), RANTES, pulmonary and activation-regulated chemokine (PARC), IL-2Rg, metallomatrixproteinase-9 (MMP-9), IL-17, fibronectin, interferon inducible T-cell alpha chemoattractant (ITAC), myeloperoxidase (MPO), IL-1b, sTNF-R1, TNF-a, Abbreviations: IL, interleukin; sTNF-R2, soluble tumour necrosis factor receptor 2; IP-10, interferon gamma inducible CXCL10; TIMP1, tissue inhibitor of metalloproteinase-1; MPIF1, myeloid progenitor inhibitory factor-1; ICAM1, intercellular adhesion molecule-1; VEGF, vascular endothelial growth factor; MCP-1, monocyte chemoattractant protein-1; IL-12p40; BDNF, brain-derived neurotrophic growth factor; MIP1b, macrophage inflammatory protein-1b; ACRP30, adipocyte complementrelated protein of 30 kDa; ENA78, epithelial neutrophil activating peptide; bNGF, nerve growth factor, IL-15; TGF-a transforming growth factor-a; PARC, pulmonary and activation-regulated chemokine; IFN-g, interferon-g; MMP-9, metallomatrixproteinase-9; ITAC, interferon inducible T-cell alpha chemoattractant; MPO, myeloperoxidase; IL-12p40, Interleukin-12p40 subunit.
IL-8, and amphiregulin. These serum biomarkers included the 25 biomarkers that were identified in the study by Pinto-Plata et al. [2007] , additional markers were available for the analysis because of the format of the assay giving a total of 34 biomarkers for this study. Many of the additional markers represent processes that have been implicated in COPD pathogenesis [Barnes et al. 2003 ].
Statistical analysis
As there was skewness in the distribution of the serum biomarkers, all values were log-transformed for analytic purposes. We used a t-test to compare difference in the log-transformed serum biomarker values from visit 2 (i.e. at the time of randomisation) to visit 3 (at the end of the randomised trial phase) between the group treated with corticosteroids and the group treated with placebo. We did not adjust for multiple comparisons, as the analyses were considered exploratory in nature [Bender and Lange, 2001] .
To determine the validity of results from the SearchLight TM multiplex system with those obtained from standard commercially available enzyme-linked immunosorbent assay (ELISA) kits (RandD Systems, Minneapolis, MN), we measured MCP-1 levels in the same sera using both techniques. We chose MCP-1 because we had previously optimised and validated this measurement in our laboratory using standard ELISA with a coefficient of variation of measurement of 3.2% (median; interquartile range, 1.55.9%) . We also compared the changes in biomarkers observed with inhaled and oral corticosteroids. We included only biomarkers that changed with a p value of 0.2 or less relative to placebo. This threshold was chosen to minimise the risk of type 2 error. Continuous variables are expressed as mean± SD, unless otherwise specified. The study received approval from the University of British Columbia/Providence Health Care Ethics Board.
Results
There were 41 participants who completed the study; 12 of them were assigned to placebo (29%), 15 to fluticasone (37%), and 14 to prednisone (34%). The average age of the patients was 64±9 years and 71% (n ¼ 29) were men. The average FEV 1 was 1.68±0.67 l (55%±18% of predicted), FVC was 3.13±1.12 l (83%±20% of predicted), and FEV 1 /FVC was 52% ±12%.
Of the total, 20% (n ¼ 8) were current smokers (representing 25% of those assigned to placebo, 13% of those assigned to fluticasone and 21% of those assigned to prednisone) and 64% (n ¼ 27) were on an inhaled corticosteroid at visit 1. For MCP-1, there was a good correlation between levels obtained using standard ELISA and those obtained with the multiplex system, especially in patients who received placebo (r 2 = 0.73; p < 0.001; see Figure 1 ). When the data from all three groups were combined, the correlation remained robust (r 2 ¼ 0.52; p < 0.001).
The variability of the serum biomarkers were examined using the group that received placebo. Over 2 weeks, 23 of the 34 biomarkers (68%) had a correlation p value of less than 0.05 indicating the stability of these measurements (Table 1) . However, sTNFR-1 ( p ¼ 0.208), Compared with changes observed with placebo, inhaled fluticasone significantly reduced sTNF-R2 by 24% (95% CI, 738%; p ¼ 0.01), MCP-1 by 20% (95% CI, 532%; p ¼ 0.01), IP-10 by 43% (95% CI, 366%; p ¼ 0.04), and L-selectin by 15% (95% CI, 128%; p ¼ 0.04). Oral prednisone reduced sTNF-R2 by 26% (95% CI, 1536%; p < 0.001), L-selectin by 22% (95% CI, 834%; p ¼ 0.004), ICAM by 31% (95% CI, 948%; p ¼ 0.01), PARC by 18% (95% CI, 232%; p ¼ 0.03) and IP-10 by 40% (95% CI, 064%; p ¼ 0.05) (see Table 1 ). Only sTNF-R2, L-selectin and IP-10 were significantly reduced by both oral and inhaled corticosteroids (see Figure 2 ). When we considered biomarkers that had a p value of 0.2 or less with both inhaled and oral corticosteroids (i.e. biomarkers that were likely to be impacted by these therapies), there was a reasonable (though nonsignificant) concordance between the changes observed with inhaled fluticasone and those observed with prednisone (r 2 ¼ 0.47; p ¼ 0.09; see Figure 3 ).
Discussion
In this study we have extended the findings of Pinto-Plata et al. the stability and utility of the panel of biomarkers identified in patients with COPD. The results reported here demonstrate reasonable stability of the serum biomarker measurements over a 2-week period in the same individuals with COPD, suggesting at least in the short term that most serum biomarker measurements are robust. We also found that 2 weeks of corticosteroids reduced sTNF-R2, L-selectin, MCP-1, ICAM, IP-10 and TIMP-1 levels in stable COPD patients. Of these, only sTNF-R2, L-selectin and IP-10 levels were significantly reduced by both inhaled fluticasone and oral prednisone.
This study provides validity to the initial report by Pinto-Plata and colleagues [2007] who using a novel serum proteomic rolling cycle amplification technique were able to document differences in serum biomarker profile between patients with COPD and age matched controls. In that study a panel of 25 out of 143 biomarkers also correlated with clinical expressions of the disease such as FEV 1 , dyspnoea, diffusion capacity for carbon monoxide (DLCO), 6-minute walk distance and the multidimensional BODE index. Interestingly, the panel was also able to identify patients who exacerbated over the year of prospective observation.
This study also addressed the question related to the stability of proteomic signals over time and very importantly, their potential use in the testing of responses to pharmacological interventions. That the technique is reproducible is supported by the significant correlations between the multiplex array system and those obtained by traditional ELISA methodology, as shown for MCP-1 in Figure 1 . Whether this applies to other cytokines is uncertain. In addition, at least over the 2 weeks of the study, the majority of the biomarkers demonstrated significant stability as shown in Table 2 . Whether the same will hold true for longer periods of time remains to be determined, but this initial information is very encouraging.
The changes observed with the administration of corticosteroids are also important because they prove that the biomarker panel is capable of showing rapid and significant response to pharmacological interventions. Although we do not pretend to state that these findings are definitive, it is interesting that they are consistent with previous reports. Keh et al. [2003] showed that low-dose systemic corticosteroid therapy reduces circulating L-selectin levels in patients with septic shock. Since adhesion molecules such as L-selectin facilitate leukocyte adhesion and penetration into vascular wall (the site of atherosclerosis), by reducing circulating L-selectin levels, corticosteroids may attenuate inflammatory reactions in vascular beds. Consistent with this hypothesis, Kadioglu and Sheldon [1998] demonstrated in a short-term experiment that corticosteroids significantly reduced circulating mononuclear cells, especially T lymphocytes, and decreased their ability to adhere to vessels. Plasma levels of soluble selectins are important predictors of cardiovascular events and mortality [Blankenberg et al. 2003 ].
The present study also suggests that corticosteroids may downregulate other inflammatory molecules including sTNF-R2, IP-10 and adhesion molecules. The data for sTNF-R2 is similar to that reported by Schuld and co-workers, who found that systemic corticosteroids effected a large reduction in plasma sTNF-R2 levels and much lesser reduction in sTNF-R1 levels [Schuld et al. 2001] . In the Nurse's Health Study [Shai et al. 2005] , raised sTNF-R2 levels were associated with increased risk of myocardial infarction and other coronary heart events independent of smoking, body weight and other cardiovascular risk factors (the relative risks comparing extreme quartiles of sTNF-R2 were 2.5 for myocardial infarction and 2.0 for total coronary heart disease). Interestingly, Pai and coworkers showed that sTNF-R2 is a risk factor for coronary heart disease in women but not in men [Pai et al. 2004 ]. This raises the possibility that corticosteroids may be more effective in women than in men through their effects on this cytokine. A prospective study is needed to test this hypothesis.
There is increasing evidence that corticosteroids, especially in low doses, may provide positive cardiovascular outcomes. Huiart and coworkers, for instance, reported a 32% reduction in the risk for acute myocardial infarction when COPD patients were dispensed low-dose inhaled corticosteroids compared with nonusers of corticosteroids [Huiart et al. 2005] . Similarly, Macie et al. demonstrated a 38% reduction in cardiovascular mortality when COPD patients were treated with inhaled corticosteroids compared with nonusers [Macie et al. 2006 ]. In a post-hoc analysis of a large randomised controlled trial, the EUROSCOP trial investigators demonstrated a 40% reduction in cardiovascular event rate in patients who were assigned to inhaled budesonide compared with those assigned to placebo over a 3 year period [Lofdahl et al. 2007 ]. Parimon et al. [2007] reported a 60% relative risk reduction in lung cancer death among COPD patients who used inhaled corticosteroids.
A study of inhaled corticosteroids and longacting b 2 agonists indicate that combination therapy has a significant impact on airway lymphocyte count in patients with stable COPD over a 3 month period [Barnes et al. 2006 ]. Our findings suggest that by repressing IP-10, a potent T cell chemoattractant that acts through the CXCR3 receptor complex, corticosteroids may downregulate recruitment of lymphocytes into the lungs of COPD patients. However, corticosteroids have other pleotrophic effects on lymphocytes that may also result in their depletion in the airways through IP-10 independent pathways [Ohta and Yamashita, 1999] . Notably, many molecules that we evaluated were relatively unaffected by short term inhaled or oral corticosteroids. However, long-term studies will be needed to see if length of intervention or dose has a different effect on these biomarkers. Abbreviations: IL, interleukin; sTNF-R2, soluble tumour necrosis factor receptor 2; IP-10, interferon gamma inducible CXCL10; TIMP1, tissue inhibitor of metalloproteinase-1; MPIF1, myeloid progenitor inhibitory factor-1; ICAM1, intercellular adhesion molecule-1; VEGF, vascular endothelial growth factor; MCP-1, monocyte chemoattractant protein-1; IL-12p40; BDNF, brain-derived neurotrophic growth factor; MIP1b, macrophage inflammatory protein-1b; ACRP30, adipocyte complement-related protein of 30 kDa; ENA78, epithelial neutrophil activating peptide; bNGF, nerve growth factor; IL-15; TGF-a, transforming growth factor-a; PARC, pulmonary and activation-regulated chemokine; IFN-g, interferong; MMP-9, metallomatrixproteinase-9; ITAC, interferon inducible T-cell alpha chemoattractant; MPO, myeloperoxidase.
There were limitations to this study. Firstly, we measured only a number of serum biomarkers. We chose the biomarkers on the basis of biological plausibility as potential players in COPD pathobiology and their capacity to differentiate between patients with COPD and controls [Pinto-Plata et al. 2007 ]. There are likely to be other molecules not measured which may be important. Future work is needed to identify these molecules and to determine their responsiveness to interventions. Secondly, even with a limited selection of biomarkers, multiple comparisons were involved. As recommended by Bender and Lange, we did not use a corrective factor to adjust for multiple comparisons because these analyses were exploratory in nature [Bender and Lange, 2001] . Thus, the p values reported in this study should be interpreted cautiously. While type 1 errors are possible, it was assuring that cytokines such as IL-15, which have been noted previously to be refractory to corticosteroids even in high doses were indeed not repressed by either oral or inhaled corticosteroids in the present study [Stoeck et al. 2000 ].
In summary, in this exploratory trial, oral and inhaled corticosteroids were found to repress some but not all inflammatory cytokines in COPD patients. IP-10, L-selectins, MCP-1 and sTNF-R2 appeared to be most responsive cytokines to corticosteroids. Since these cytokines may be involved in the pathogenesis of atherosclerosis, by repressing these and other cytokines, corticosteroids may reduce cardiovascular events in COPD patients. This hypothesis will need to be validated with a much larger clinical trial. It is also notable that a majority of cytokines that were evaluated in the present study did not materially change with either inhaled or oral corticosteroids. Further studies involving other pharmacological agents may help clarify the way in which therapy could influence different outcomes.
